BAYRY - Bayer AG Stock Price, News & Analysis

$32.05 -0.15 (-0.47 %)
(As of 11/22/2017 04:00 PM ET)
Previous Close$32.20
Today's Range$31.89 - $32.22
52-Week Range$22.88 - $35.41
Volume197,817 shs
Average Volume454,377 shs
Market Capitalization$105.42 billion
P/E Ratio15.84
Dividend Yield1.69%
Beta1.13

About Bayer AG (OTCMKTS:BAYRY)

Bayer AG logoBayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The Pharmaceuticals division also comprises the radiology business. The Consumer Health segment is engaged in the development, production and marketing of mainly nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories. The Animal Health segment is engaged in the development, production and marketing of prescription and nonprescription veterinary products. The Covestro segment is engaged in the development, production and marketing of raw materials for polyurethanes, polycarbonate granules and sheets and raw materials for coatings, adhesives.


Industry, Sector and Symbol:
  • Industry: N/A
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: OTCMKTS:BAYRY
  • CUSIP: N/A
  • Web: www.bayer.com
Debt:
  • Debt-to-Equity Ratio: 0.40%
  • Current Ratio: 1.74%
  • Quick Ratio: 1.29%
Price-To-Earnings:
  • Trailing P/E Ratio: 15.84
  • Forward P/E Ratio: 14.57
  • P/E Growth: 2.25
Sales & Book Value:
  • Annual Sales: $51.77 billion
  • Price / Sales: 2.05
  • Cash Flow: $3.22 per share
  • Price / Cash: 9.95
  • Book Value: $10.67 per share
  • Price / Book: 3.00
Dividend:
  • Annual Dividend: $0.54
  • Dividend Yield: 1.7%
Profitability:
  • Net Income: $5.01 billion
  • Net Margins: 10.88%
  • Return on Equity: 17.92%
  • Return on Assets: 6.85%
Misc:
  • Employees: 115,200
  • Outstanding Shares: 3,307,800,000
 

Frequently Asked Questions for Bayer AG (OTCMKTS:BAYRY)

What is Bayer AG's stock symbol?

Bayer AG trades on the OTCMKTS under the ticker symbol "BAYRY."

How often does Bayer AG pay dividends? What is the dividend yield for Bayer AG?

Bayer AG declared an annual dividend on Thursday, June 29th. Shareholders of record on Wednesday, May 3rd will be paid a dividend of $2.157 per share on Monday, May 15th. The ex-dividend date of this dividend is Monday, May 1st. View Bayer AG's Dividend History.

How were Bayer AG's earnings last quarter?

Bayer AG (OTCMKTS:BAYRY) posted its quarterly earnings results on Thursday, October, 29th. The company reported $1.88 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.65 by $0.23. The company earned $12.28 billion during the quarter, compared to analyst estimates of $12.79 billion. Bayer AG had a return on equity of 17.92% and a net margin of 10.88%. View Bayer AG's Earnings History.

When will Bayer AG make its next earnings announcement?

Bayer AG is scheduled to release their next quarterly earnings announcement on Wednesday, February, 28th 2018. View Earnings Estimates for Bayer AG.

Who are some of Bayer AG's key competitors?

Who are Bayer AG's key executives?

Bayer AG's management team includes the folowing people:

  • Werner Wenning, Chairman of the Supervisory Board (Age 70)
  • Werner Baumann, Chairman of the Management Board, Chief Executive Officer (Age 54)
  • Oliver Zuehlke, Vice Chairman of the Supervisory Board, Employee Representative (Age 48)
  • Johannes M. Dietsch, Chief Financial Officer, Member of the Management Board (Age 55)
  • Hartmut Klusik, Member of the Management Board, Director of Human Resources, Technology & Sustainability, Labor Director (Age 60)
  • Jennifer Brendelto, Vice President - Communications of the Consumer Health Division
  • Liam Condon, Member of the Management Board, Head of the Crop Science Division, Animal Health Business Unit (Age 48)
  • Kemal Malik, Member of the Management Board, Innovation and the Latin America Region (Age 54)
  • Erica Mann, Member of the Management Board, Head of the Consumer Health Division (Age 58)
  • Dieter Weinand, Member of the Management Board, Head of the Pharmaceuticals Division (Age 56)

How do I buy Bayer AG stock?

Shares of Bayer AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bayer AG's stock price today?

One share of Bayer AG stock can currently be purchased for approximately $32.05.

How big of a company is Bayer AG?

Bayer AG has a market capitalization of $105.42 billion and generates $51.77 billion in revenue each year. Bayer AG employs 115,200 workers across the globe.

How can I contact Bayer AG?

Bayer AG's mailing address is Kaiser-Wilhelm-Allee 1, Leverkusen 2M, 51368. The company can be reached via phone at 49-21-4-30-1 or via email at [email protected]


MarketBeat Community Rating for Bayer AG (BAYRY)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  167 (Vote Outperform)
Underperform Votes:  205 (Vote Underperform)
Total Votes:  372
MarketBeat's community ratings are surveys of what our community members think about Bayer AG and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Bayer AG (OTCMKTS:BAYRY)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 4 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Bayer AG (OTCMKTS:BAYRY)

Price Target History for Bayer AG (OTCMKTS:BAYRY)

Analysts' Ratings History for Bayer AG (OTCMKTS:BAYRY)

Show:
DateFirmActionRatingPrice TargetDetails
9/25/2017BNP ParibasUpgradeNeutral -> OutperformView Rating Details
7/3/2017Berenberg BankDowngradeBuy -> HoldView Rating Details
2/24/2017Sanford C. BernsteinReiterated RatingOutperformView Rating Details
1/4/2017J P Morgan Chase & CoUpgradeNeutral -> OverweightView Rating Details
12/19/2016Jefferies Group LLCUpgradeHold -> BuyView Rating Details
9/14/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuyView Rating Details
8/25/2016Citigroup Inc.UpgradeNeutral -> BuyView Rating Details
5/25/2016Commerzbank AgUpgradeHold -> BuyView Rating Details
5/25/2016Deutsche Bank AGReiterated RatingBuyView Rating Details
5/25/2016DZ Bank AGReiterated RatingBuyView Rating Details
4/27/2016Credit Suisse GroupDowngradeOutperform -> NeutralView Rating Details
4/8/2016Nord/LBReiterated RatingBuyView Rating Details
3/7/2016Barclays PLCUpgradeUnderweight -> Equal WeightView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Bayer AG (OTCMKTS:BAYRY)

Earnings by Quarter for Bayer AG (OTCMKTS:BAYRY)

Earnings History by Quarter for Bayer AG (OTCMKTS BAYRY)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018        
7/27/20176/30/2017$1.87$1.99$14.45 billion$13.41 billionViewN/AView Earnings Details
4/27/20173/31/2017$2.40$2.80$13.65 billion$14.11 billionViewN/AView Earnings Details
10/26/2016Q3$1.80$1.93$12.39 billion$12.57 billionViewListenView Earnings Details
10/29/2015Q3$1.65$1.88$12.79 billion$12.28 billionViewListenView Earnings Details
4/30/2015Q1 2015$2.35$2.33$12.81 billion$13.45 billionViewN/AView Earnings Details
2/26/2015Q4 2014$1.35$12.53 billionViewN/AView Earnings Details
7/30/2014Q2 2014$2.05$14.02 billionViewN/AView Earnings Details
4/24/2014Q1 2014$2.47$2.35$14.67 billion$14.59 billionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bayer AG (OTCMKTS:BAYRY)
Current Year EPS Consensus Estimate: $2.2 EPS
Next Year EPS Consensus Estimate: $2.48 EPS

Dividends

Current Dividend Information for Bayer AG (OTCMKTS:BAYRY)

Most Recent Dividend:5/15/2017
Annual Dividend:$0.54
Dividend Yield:1.68%
Payout Ratio:24.55% (Based on This Year's Estimates)
21.77% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Bayer AG (OTCMKTS:BAYRY)

Dividend History by Quarter for Bayer AG (OTCMKTS BAYRY)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/29/2017Annual$2.165/1/20175/3/20175/15/2017
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Bayer AG (OTCMKTS BAYRY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Bayer AG (OTCMKTS BAYRY)

Source:
DateHeadline
Brazils review of Bayers Monsanto takeover may be extendedBrazil's review of Bayer's Monsanto takeover may be extended
finance.yahoo.com - November 22 at 5:03 PM
Bayer AG to Post FY2017 Earnings of $2.21 Per Share, Jefferies Group Forecasts (BAYRY)Bayer AG to Post FY2017 Earnings of $2.21 Per Share, Jefferies Group Forecasts (BAYRY)
www.americanbankingnews.com - November 20 at 3:44 AM
Is Loxo Oncologys Deal With Bayer Bad News? -- The Motley Fool - Motley FoolIs Loxo Oncology's Deal With Bayer Bad News? -- The Motley Fool - Motley Fool
www.fool.com - November 18 at 9:17 PM
Is Loxo Oncology's Deal With Bayer Bad News?Is Loxo Oncology's Deal With Bayer Bad News?
finance.yahoo.com - November 18 at 4:16 PM
Jefferies Group Comments on Bayer AGs FY2017 Earnings (BAYRY)Jefferies Group Comments on Bayer AG's FY2017 Earnings (BAYRY)
www.americanbankingnews.com - November 17 at 9:44 PM
Heres Why Nektar Therapeutics Is Skyrocketing 70% in NovemberHere's Why Nektar Therapeutics Is Skyrocketing 70% in November
www.fool.com - November 16 at 11:47 AM
Bayer AG (BAYRY) Receives Average Recommendation of "Buy" from BrokeragesBayer AG (BAYRY) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 16 at 1:32 AM
Bayer AG to Post FY2020 Earnings of $2.47 Per Share, Jefferies Group Forecasts (BAYRY)Bayer AG to Post FY2020 Earnings of $2.47 Per Share, Jefferies Group Forecasts (BAYRY)
www.americanbankingnews.com - November 15 at 4:28 PM
Monsanto (MON) Premium Herbicide Declared Non-Carcinogenic - NasdaqMonsanto (MON) Premium Herbicide Declared Non-Carcinogenic - Nasdaq
www.nasdaq.com - November 14 at 4:53 PM
Bayer Bets Big on a Tiny Cancer Drug Up-and-Comer - Motley FoolBayer Bets Big on a Tiny Cancer Drug Up-and-Comer - Motley Fool
www.fool.com - November 14 at 4:53 PM
Loxo Oncology to develop, commercialize cancer drugs with BayerLoxo Oncology to develop, commercialize cancer drugs with Bayer
finance.yahoo.com - November 14 at 4:53 PM
Loxo announces $400 mln Bayer cancer partnershipLoxo announces $400 mln Bayer cancer partnership
finance.yahoo.com - November 14 at 4:53 PM
Monsanto (MON) Premium Herbicide Declared Non-CarcinogenicMonsanto (MON) Premium Herbicide Declared Non-Carcinogenic
finance.yahoo.com - November 14 at 4:53 PM
Loxo signs lucrative cancer drug deal with Bayer, but shares fallLoxo signs lucrative cancer drug deal with Bayer, but shares fall
finance.yahoo.com - November 14 at 4:53 PM
This Cancer Biotech Is Falling On Its $1.55 Billion Bayer DealThis Cancer Biotech Is Falling On Its $1.55 Billion Bayer Deal
finance.yahoo.com - November 14 at 4:53 PM
Biotechs Sell Off In Droves — Are Investors Seeking Mergers?Biotechs Sell Off In Droves — Are Investors Seeking Mergers?
finance.yahoo.com - November 14 at 4:53 PM
ETFs with exposure to Bayer AG : November 13, 2017ETFs with exposure to Bayer AG : November 13, 2017
finance.yahoo.com - November 14 at 1:36 AM
Monsanto: Important To National Security? (Lawmakers Against Acquisition Say Yes)Monsanto: Important To National Security? (Lawmakers Against Acquisition Say Yes)
seekingalpha.com - March 20 at 10:00 AM
Roche Restructuring Shows Trouble in US Diabetes Biz (RHHBY)Roche Restructuring Shows Trouble in US Diabetes Biz (RHHBY)
www.investopedia.com - March 17 at 4:29 PM
Roche Restructuring Shows Trouble in US Diabetes BizRoche Restructuring Shows Trouble in US Diabetes Biz
www.investopedia.com - March 17 at 4:29 PM
CRISPR Therapeutics and JV with Bayer nab non-exclusive rights to MaxCytes cell engineering platformCRISPR Therapeutics and JV with Bayer nab non-exclusive rights to MaxCyte's cell engineering platform
seekingalpha.com - March 14 at 3:44 PM
Dow Chemical Subsidiary Must Pay $456 Million Award to BayerDow Chemical Subsidiary Must Pay $456 Million Award to Bayer
www.thestreet.com - March 2 at 4:03 PM
Trumps Anti-Pot Stance Wont Hurt This Canna-Business StockTrump's Anti-Pot Stance Won't Hurt This 'Canna-Business' Stock
www.thestreet.com - March 2 at 4:03 PM
Bayer sells 11 pct of Covestro for 1.46 bln eurosBayer sells 11 pct of Covestro for 1.46 bln euros
us.rd.yahoo.com - March 1 at 3:48 PM
Bayer Looks Beyond Xarelto And Eylea - Seeking AlphaBayer Looks Beyond Xarelto And Eylea - Seeking Alpha
seekingalpha.com - February 28 at 12:10 PM
Bayers Q4: Mixed Signals For InvestorsBayer's Q4: Mixed Signals For Investors
seekingalpha.com - February 23 at 3:50 PM
Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line - NasdaqBayer (BAYRY) Misses on Q4 Earnings; Revenues in Line - Nasdaq
www.nasdaq.com - February 23 at 3:50 PM
Bayer outlines Monsanto deal financing - Seeking AlphaBayer outlines Monsanto deal financing - Seeking Alpha
seekingalpha.com - February 23 at 3:50 PM
[$$] Fusion Pharmaceuticals Raises $25 Million for Targeted Cancer Therapies[$$] Fusion Pharmaceuticals Raises $25 Million for Targeted Cancer Therapies
www.wsj.com - February 23 at 3:50 PM
[$$] Bayer Details Financing Plan for Monsanto Deal[$$] Bayer Details Financing Plan for Monsanto Deal
www.wsj.com - February 22 at 3:52 PM
Bayer Offers Further Detail on Financing Monsanto TakeoverBayer Offers Further Detail on Financing Monsanto Takeover
www.thestreet.com - February 22 at 3:52 PM
Bayer Q4 Profit Down 26%; Sees Higher Earnings, Sales In FY17 - Quick FactsBayer Q4 Profit Down 26%; Sees Higher Earnings, Sales In FY17 - Quick Facts
www.rttnews.com - February 22 at 11:50 AM
Bayer Hints at Delay on Monsanto as Regulators Seek DetailsBayer Hints at Delay on Monsanto as Regulators Seek Details
us.rd.yahoo.com - February 22 at 11:50 AM
Bayer Shares Drop After Cautious 2017 Outlook For Crop Science UnitBayer Shares Drop After Cautious 2017 Outlook For Crop Science Unit
us.rd.yahoo.com - February 22 at 11:50 AM
European Stocks Extend Gains as Economic Data Continues to ImpressEuropean Stocks Extend Gains as Economic Data Continues to Impress
us.rd.yahoo.com - February 22 at 11:50 AM
[$$] Bayer CEO Confident Monsanto Purchase Will Be Approved by End of Year[$$] Bayer CEO Confident Monsanto Purchase Will Be Approved by End of Year
us.rd.yahoo.com - February 22 at 11:50 AM
Bayer confident about Monsanto deal - Seeking AlphaBayer confident about Monsanto deal - Seeking Alpha
seekingalpha.com - February 22 at 11:50 AM
Bayer says Monsanto deal on track, eyes record 2017Bayer says Monsanto deal on track, eyes record 2017
uk.finance.yahoo.com - February 22 at 11:50 AM
Bayer Proposes Increased Dividend For 2016 - Quick Facts - NasdaqBayer Proposes Increased Dividend For 2016 - Quick Facts - Nasdaq
www.nasdaq.com - February 21 at 11:18 AM
Bayer Proposes Increased Dividend For 2016 - Quick FactsBayer Proposes Increased Dividend For 2016 - Quick Facts
www.rttnews.com - February 21 at 11:18 AM
Wagering on a Megadeal… With Warren Buffett?Wagering on a Megadeal… With Warren Buffett?
www.bloomberg.com - February 14 at 8:26 PM
Americans with last name Smith are focal point of Bayer Aspirins new ad campaignAmericans with last name Smith are focal point of Bayer Aspirin's new ad campaign
www.bizjournals.com - February 10 at 4:21 PM
Bayers Xarelto Eases Artery Disease (BAYRY)Bayer's Xarelto Eases Artery Disease (BAYRY)
www.investopedia.com - February 9 at 3:58 PM
Bayer’s Blood Thinner Works for Artery DiseaseBayer’s Blood Thinner Works for Artery Disease
www.investopedia.com - February 9 at 3:58 PM
Regeneron (REGN) Q4 Earnings: Will the Stock Disappoint?Regeneron (REGN) Q4 Earnings: Will the Stock Disappoint?
www.zacks.com - February 8 at 4:01 PM
Bayers rivaroxaban successful in reducing cardiovascular event risk in late-stage studyBayer's rivaroxaban successful in reducing cardiovascular event risk in late-stage study
seekingalpha.com - February 8 at 4:01 PM
10:37 am Bayer AG reports Phase III COMPASS study with Bayers Rivaroxaban in patients with coronary or peripheral artery disease shows overwhelming efficacy and meets primary endpoint early10:37 am Bayer AG reports Phase III COMPASS study with Bayer's Rivaroxaban in patients with coronary or peripheral artery disease shows overwhelming efficacy and meets primary endpoint early
us.rd.yahoo.com - February 8 at 4:01 PM
Moodys: German Non-Financial Companies to Issue Record Bond Volumes in 2017Moody's: German Non-Financial Companies to Issue Record Bond Volumes in 2017
www.moodys.com - February 7 at 4:45 PM
Roche Denies Reports It Plans to Exit Diabetes Business (RHHBY)Roche Denies Reports It Plans to Exit Diabetes Business (RHHBY)
www.investopedia.com - February 1 at 3:59 PM
Roche Denies Reports It Plans to Exit Diabetes BusinessRoche Denies Reports It Plans to Exit Diabetes Business
www.investopedia.com - February 1 at 3:59 PM

Social Media

Financials

Financials are not available for this stock.

Chart

Bayer AG (OTCMKTS BAYRY) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.